Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Medulloblastoma label free proteome analysis from an Indian subpopulation

ABSTRACT: The label free tissue proteomic analysis of medulloblastoma proteome was perfomed for the identification of protein markers for the developinment of IHC markers for the diagnostic purpose. The pathway al;tyerations and protein signatures of G3 tumor is the major focus.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Early Embryonic Cell

DISEASE(S): Brain Cancer

SUBMITTER: Manubhai K P

LAB HEAD: Dr.Sanjeeva Srivastava

PROVIDER: PXD014950 | Pride | 2021-04-30

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	01022018_Fusion_Manu_MB_Combinedanalysis_Insol.msf	Msf
	MB_F11.RAW.raw	Raw
	MB_F12.RAW.raw	Raw
	MB_F13.RAW.raw	Raw
	MB_F14.RAW.raw	Raw

Items per page:

1 - 5 of 24

Similar Datasets

Musashi-1 is a master regulator of aberrant translation in Group 3 medulloblastoma

Project description:Transcripts bound to Musashi-1 (MSI1) are explored in Group 3 medulloblastoma (G3 MB) and neural stem cells harvested from the cerebellar portion of a embryonal brain

2022-10-28 | GSE126263 | GEO

Epigenetic methylation chip analysis of childhood medulloblastoma patient samples

Project description:DNA methylation analysis was perfomed using Infinium EPIC Methylation BeadChip platform on 29 patient samples. Resulting .idat files were then uploaded to the molecularneuropathology.org classifier to obtain molecular subgroup and copy number variance. This data was further assigned to medulloblastoma subtypes by Martin Sill (DFKZ, Heidelberg, Germany).

2021-06-04 | GSE156012 | GEO

Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma

Project description:We devised a high-throughput, cell-based assay to identify novel therapeutic compounds to treat Group3 medulloblastoma (G3 MB). Mouse G3 MBs, grown as neurospheres, were screened against a library of approximately 7,000 compounds including FDA-approved drugs. We identified two FDA-approved drugs, pemetrexed and gemcitabine that preferentially inhibited tumor proliferation in vitro compared to control neurospheres, and substantially inhibited tumor proliferation in vivo. When combined, the two drugs significantly increased survival

2014-04-15 | GSE46406 | GEO

Analysis of Gene Expression in Medulloblastoma

Project description:The objective is to investigate epigenetic markers in medulloblastoma

2017-03-04 | GSE95684 | GEO

Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma

2014-04-15 | E-GEOD-46406 | biostudies-arrayexpress

Novel MYC-driven medulloblastoma models generated by CRISPR activation of endogenous Myc

Project description:Myc-driven Group 3 (G3) medulloblastoma (MB) is the most aggressive tumor among the four subgroups classified by transcriptome, genomic landscape and clinical outcomes. Several successful mouse models have been developed to recapitulate G3 MB tumor development; however, all models currently used facilitate tumorigenesis by constitutive ectopic expression of exogenously regulated Myc randomly integrated in multiple events into the genome. To overcome limitations of ectopically expressed Myc models, we used nuclease deficient CRISPR/dCas9-based transactivators in combination with specific single guide RNA (sgRNA) to force the transcriptional activation of endogenous Myc in Trp53-null neurosphere cells followed by orthotopic transplantations. Combination of three sgRNAs with dCas9-VP64 induced endogenous Myc expression and formed large cell anaplastic MBs which recapitulated the molecular characteristics of other mouse G3 MBs. This novel model more closely mimics human Myc-driven G3 MB disease development, and will be a valuable tool for future pre-clinical and therapeutic studies.

2018-06-12 | GSE102096 | GEO

Proteomic research on effect of EIF4A1 inhibition in MYC-amplified Group 3 medulloblastoma

Project description:As the most life-threatening subtype of pediatric medulloblastoma (MB), MYC-amplified Group 3 (G3) MB lacks effective and selective therapeutics. We tried to indirectly target MYC (oncogenic driver and cancer-dependent molecule) production via inhibiting translational machinery. Through multiple datasets analyses on components of eIF4F (eukaryotic translation initiation factor 4F) complex, we found that EIF4A1 (major component with RNA helicase activity) has relatively higher expression level and the closest positive correlation with MYC in G3-MB among normal control and other 3 subtypes (e.g., WNT, SHH and G4). Both in vitro and in vivo experiments with MYC-amplified G3-MB cell lines showed effective growth inhibition upon EIF4A1 knockout or inhibitor treatment. Further FACS analysis found decreased cell proliferation and enhanced apoptosis on EIF4A1 inhibitor treatment. To explore the mechanisms of EIF4A1 inhibition on arresting MYC-amplified G3-MB, we performed the whole proteome analyses on corresponding MB cells treated with EIF4A1 inhibitor.

2020-10-15 | PXD022014 |

Exome sequencing analysis of murine medulloblastoma models identifies Wdr11 as a potential tumor suppressor in Group 3 tumors

Project description:We previoiusly identified WDR11 as a potential tumor suppressor in murine medulloblastoma models. To determine additional genes/pathways affected by WDR11 overexpression.To compare somatic mutations of murine models with human medulloblastoma (MB), we performed whole-exome sequencing of mouse tumors representing three distinct MB subgroups: Wnt, Sonic Hedgehog (Shh) and Group 3 (G3). 64 somatic mutations were identified and validated, including 40 predicted to cause amino acid changes. After filtering and cross-species analysis with 366 human MBs from four independent studies, human orthologs for 16 of the 40 mouse genes were found to harbor non-silent mutations in human MB. Loss-of-function Mll2 mutations detected in one mouse tumor were previously reported in 30 of 366 human MBs. In mice with G3 MB, one mouse that died at least 15 days earlier than the others had four novel candidate genes harboring non-silent somatic mutations, Lrfn2, Smyd1, Ubn2 and Wdr11. To test whether these genes had tumor suppressive activity, we constitutively overexpressed each wild type gene in murine G3 tumorspheres followed by intracranial implantation. Mice harboring mouse G3 MB overexpressing WDR11 showed extended survival compared to the other three genes. Genes in the KEGG WNT signaling pathway, including Ccnd1/2/3, Myc and Tcf7l1, were down-regulated in G3 MB tumorspheres overexpressing WDR11, consistent with reduced tumor progression. In conclusion, we demonstrated that common spontaneous mutations were shared between human and murine models of MB suggesting similar molecular mechanisms of tumorigenesis, and identified WDR11 as a protein with tumor suppressive activity in G3 MB.

2017-10-17 | GSE101767 | GEO

Inactivation of Ezh2 upregulates Gfi1 and drives aggressive Myc-driven Group 3 medulloblastoma [ChIP-Seq]

Project description:The most aggressive of four medulloblastoma (MB) subgroups are cMYC-driven Group 3 (G3) tumors, some of which overexpress EZH2, the histone H3K27 trimethylase of polycomb repressive complex-2. Yet, engineered deletions of Ezh2 in G3 MBs by gene editing nucleases accelerated tumorigenesis, whereas Ezh2 re-expression reversed attendant histone modifications and slowed tumor progression. Candidate oncogenic drivers upregulated following Ezh2 deletion included Gfi1, a proto-oncogene frequently activated in human G3 MBs. Gfi1 disruption antagonized the tumor promoting effects of Ezh2 loss; conversely, Gfi1 overexpression collaborated with Myc to bypass effects of Trp53 inactivation in primary cerebellar neuronal progenitors thereby driving MB progression. Although negative epigenetic regulation of Gfi1 by Ezh2 may restrain MB development, Gfi1 activation can bypass these effects.

2017-03-01 | GSE84761 | GEO

Inactivation of Ezh2 upregulates Gfi1 and drives aggressive Myc-driven Group 3 medulloblastoma [RNA-Seq]

2017-03-01 | GSE84462 | GEO